Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.117682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Zehua He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody o…. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, Triple Negative Breast Neoplasms, B7-H1 Antigen, Artemisinins. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Pudong New Area Health Commission.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) remains a clinical challenge due to limited therapeutic options and frequent resistance to immunotherapy. While PD-L1 blockade shows promise, clinical responses are often inadequate. Here we demonstrated that augmenting PD-L1 expression on TNBC cells significantly enhances the efficacy of anti-PD-L1 therapy in murine models. Through a high-throughput screen of FDA-approved compounds, artemether (ART) emerged as a robust inducer of PD-L1 surface expression in multiple murine and human TNBC cell lines. Mechanistically, ART disrupts the interaction between the E3 ubiquitin ligase adaptor KEAP1 and PD-L1, preventing KEAP1-mediated PD-L1 degradation and enhancing its stability and membrane localization. Concurrently, ART-induced KEAP1 inhibition activates NRF2, leading to increased PD-L1 transcription. Critically, in syngeneic TNBC mouse models, ART synergistically enhanced the antitumor efficacy of atezolizumab, promoting tumor regression and increasing intratumoral CD8+ T cell infiltration and cytotoxicity. Our findings reveal a novel mechanism by which ART upregulates PD-L1 through KEAP1 inhibition and establish ART as a promising pharmacological agent to improve the clinical outcomes of PD-L1 checkpoint blockade immunotherapy in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, School of Pharmaceutical Sciences, State…
- Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University Nanjing, Jiangsu, China.
- Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University Nanjing, Jiangsu, China. Electronic address: linfee@me.com.
- Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: xlqlily@163.com.
Förderung
- National Natural Science Foundation of China
- Shanghai Pudong New Area Health Commission
Zitieren
APA
He, Z., Chen, Z., Wang, L., Hu, Z., Wang, Z., Zhou, J., Zhu, Y., Lyu, Z., Zhang, W., Lin, F., Cao, X., & Xue, L. (2026). Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117682
Vancouver
He Z, Chen Z, Wang L, Hu Z, Wang Z, Zhou J, et al. Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117682
BibTeX
@article{He2026,
author = {He, Zehua and Chen, Zhaoshuai and Wang, Lei and Hu, Ziyi and Wang, Zhixin and Zhou, Jiehang and Zhu, Yiran and Lyu, Zhaorui and Zhang, Wencan and Lin, Fan and Cao, Xu and Xue, Liqiong},
title = {Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.117682}
}
EUVIMED